[{"id":"d1651a97-e0b7-453b-880d-d4d563121330","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834373","created_at":"2025-02-25T13:57:53.594Z","updated_at":"2025-02-25T13:57:53.594Z","phase":"Phase 2","brief_title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","source_id_and_acronym":"NCT06834373","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2025","start_date":" 03/03/2025","primary_txt":" Primary completion: 03/03/2027","primary_completion_date":" 03/03/2027","study_txt":" Completion: 03/03/2027","study_completion_date":" 03/03/2027","last_update_posted":"2025-02-20"},{"id":"ffcc36de-86c4-4efe-bf14-26220583e249","acronym":"TOP-FLOR","url":"https://clinicaltrials.gov/study/NCT05788081","created_at":"2023-03-28T14:05:15.158Z","updated_at":"2025-02-25T14:17:47.899Z","phase":"Phase 2","brief_title":"Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.","source_id_and_acronym":"NCT05788081 - TOP-FLOR","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-26"},{"id":"92b33b60-daf2-458f-b368-c4bd957a3d7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05354557","created_at":"2022-04-29T11:55:52.474Z","updated_at":"2024-07-02T16:35:22.512Z","phase":"Phase 2","brief_title":"Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)","source_id_and_acronym":"NCT05354557","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iberdomide (CC-220)"],"overall_status":"Recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/26/2025","primary_completion_date":" 04/26/2025","study_txt":" Completion: 04/26/2025","study_completion_date":" 04/26/2025","last_update_posted":"2024-01-23"},{"id":"d361ee88-d87a-4fe2-9be4-8b2ce4671cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04464798","created_at":"2021-07-05T17:31:08.177Z","updated_at":"2024-07-02T16:35:34.824Z","phase":"Phase 1/2","brief_title":"A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas","source_id_and_acronym":"NCT04464798","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Gazyva (obinutuzumab) • iberdomide (CC-220)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 01/02/2025","study_completion_date":" 01/02/2025","last_update_posted":"2023-10-04"},{"id":"6ff06964-4a4d-4f6c-8623-c8cc6737eeca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04882163","created_at":"2021-05-11T11:53:08.827Z","updated_at":"2024-07-02T16:36:23.460Z","phase":"Phase 1b/2","brief_title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","source_id_and_acronym":"NCT04882163","lead_sponsor":"Celgene","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • dexamethasone • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • iberdomide (CC-220)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2021","start_date":" 10/10/2021","primary_txt":" Primary completion: 04/08/2026","primary_completion_date":" 04/08/2026","study_txt":" Completion: 04/07/2029","study_completion_date":" 04/07/2029","last_update_posted":"2021-10-05"}]